PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACA ...
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2410
https://www.valueinhealthjournal.com/article/S1098-3015(18)35712-7/fulltext
Title :
PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACA ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35712-7&doi=10.1016/j.jval.2018.09.2410
First page :
Section Title :
Open access? :
No
Section Order :
1765